company background image

Biomerica NasdaqCM:BMRA Stock Report

Last Price


Market Cap







28 Jun, 2022


Company Financials
BMRA fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

BMRA Stock Overview

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide.

Biomerica Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biomerica
Historical stock prices
Current Share PriceUS$2.99
52 Week HighUS$7.38
52 Week LowUS$2.65
1 Month Change-10.48%
3 Month Change-33.70%
1 Year Change-25.06%
3 Year Change14.12%
5 Year Change10.23%
Change since IPO-14.57%

Recent News & Updates

Dec 03
Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Despite strong share price growth of 66% for Biomerica, Inc. ( NASDAQ:BMRA ) over the last few years, earnings growth...

Shareholder Returns

BMRAUS Medical EquipmentUS Market

Return vs Industry: BMRA underperformed the US Medical Equipment industry which returned -24% over the past year.

Return vs Market: BMRA underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is BMRA's price volatile compared to industry and market?
BMRA volatility
BMRA Average Weekly Movement9.9%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: BMRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: BMRA's weekly volatility (10%) has been stable over the past year.

About the Company

197166Zack Irani

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company’s diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient’s body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.

Biomerica Fundamentals Summary

How do Biomerica's earnings and revenue compare to its market cap?
BMRA fundamental statistics
Market CapUS$38.56m
Earnings (TTM)-US$3.51m
Revenue (TTM)US$14.62m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMRA income statement (TTM)
Cost of RevenueUS$12.12m
Gross ProfitUS$2.50m
Other ExpensesUS$6.01m

Last Reported Earnings

Feb 28, 2022

Next Earnings Date


Earnings per share (EPS)-0.27
Gross Margin17.09%
Net Profit Margin-23.98%
Debt/Equity Ratio0%

How did BMRA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is BMRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BMRA?

Other financial metrics that can be useful for relative valuation.

BMRA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA-8.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BMRA's PS Ratio compare to its peers?

BMRA PS Ratio vs Peers
The above table shows the PS ratio for BMRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average8.6x
ECOR electroCore
BIEL BioElectronics
PEYE Precision Optics Corporation
AWH Aspira Women's Health
BMRA Biomerica

Price-To-Sales vs Peers: BMRA is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (8.6x).

Price to Earnings Ratio vs Industry

How does BMRA's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: BMRA is good value based on its Price-To-Sales Ratio (2.6x) compared to the US Medical Equipment industry average (4x)

Price to Sales Ratio vs Fair Ratio

What is BMRA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BMRA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BMRA's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of BMRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BMRA ($2.99) is trading below our estimate of fair value ($13.34)

Significantly Below Fair Value: BMRA is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMRA's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Biomerica forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomerica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine whether Biomerica is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.

Past Performance

How has Biomerica performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BMRA is currently unprofitable.

Growing Profit Margin: BMRA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: BMRA is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.

Accelerating Growth: Unable to compare BMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).

Return on Equity

High ROE: BMRA has a negative Return on Equity (-35.93%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Biomerica's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BMRA's short term assets ($15.2M) exceed its short term liabilities ($6.7M).

Long Term Liabilities: BMRA's short term assets ($15.2M) exceed its long term liabilities ($1.1M).

Debt to Equity History and Analysis

Debt Level: BMRA is debt free.

Reducing Debt: BMRA had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BMRA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BMRA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 28.3% per year.

Discover healthy companies


What is Biomerica current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMRA's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BMRA has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Zack Irani (55 yo)





Mr. Zackary S. Irani, also known as Zack, has been Chairman of the Board and Chief Executive Officer of Biomerica Inc. since April 29, 1997 and served as its President. Mr. Irani serves as the President an...

CEO Compensation Analysis

Compensation vs Market: Zack's total compensation ($USD488.33K) is below average for companies of similar size in the US market ($USD752.76K).

Compensation vs Earnings: Zack's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: BMRA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Experienced Board: BMRA's board of directors are considered experienced (5.9 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.

Top Shareholders

Company Information

Biomerica, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Biomerica, Inc.
  • Ticker: BMRA
  • Exchange: NasdaqCM
  • Founded: 1971
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$38.556m
  • Shares outstanding: 12.85m
  • Website:

Number of Employees


  • Biomerica, Inc.
  • 17571 Von Karman Avenue
  • Irvine
  • California
  • 92614
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Annual Earnings2021/05/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.